VERA THERAPEUTICS

DEEP DIVE ANALYSIS

Dec 03, 2025

∙ Paid

M&A Probability: 75-80%
Timeline: 12-18 months
Target Price: $55-65
Current Price: $37.60

THE OPPORTUNITY

Vera Therapeutics is developing atacicept for IgA nephropathy, a progressive kidney disease affecting roughly 150,000 people in the US with no approved treatments. The company reported positive Phase 2b ORIGIN trial data showing statistically significant proteinuria reduction - the FDA’s accepted endpoint for accelerated approval.

Continue reading this post for free, courtesy of The M&A Hunter.

Or purchase a paid subscription.